
usd pm et
summari second largest distributor pharmaceut broad rang
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
pm stock trade
sale grew compar aid
purchas largest independ
drug distributor smith januari
retail pharmaci locat
acquir largest custom
walgreen estim
organ growth exclud
estim adjust pre-tax incom per share
fell margin continu drop
gross profit margin
driven gener drug price
deflat persist sever year
regulatori closur pharmedium
plant also hurt margin
growth sg expens greatli
rate gener deflat appear
slow sever sever year
expect help stabil earn
consolid health care payer
provid continu though
like limit abil rais price
distribut servic forecast
flat earn modest ep growth
driven share repurchas
expect see much way
earn growth
medium-term despit sale growth
move greater prescript volum
drug distributor continu face margin
pressur stem lack price
margin
trend integr among health care
provid insur pharmaci benefit
manag downstream serv
increas scale custom view
expect continu erod
price power limit margin recoveri
polit competit pressur
drug price also like persist
headwind wholes oper
target fy sept ep
forecast -- discount histor
forward price-to-earnings averag due limit
earn growth expect think
near-term organ earn growth
flat-to-neg due on-going challeng
drug distributor face risk view
pressur opioid litig failur renew
risk assess reflect view strong
long-term growth prospect drug distributor volum
age develop popul expand health
care coverag emerg market drive growth
prescript volum also think barrier entri
industri high due nation three largest
distributor possess market share
posit balanc view
extrem limit abil rais price current
environ custom consolid polit
pressur drug price increas competit
gener manufactur industri persist
fiscal year end sep ep estim base cfra
oper earn histor earn report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
execut vice-president chief
corpor overview amerisourcebergen corpor second largest pharmaceut
distribut compani primari busi entail wareh logist servic
connect manufactur brand-nam gener pharmaceut end-us outlet downstream
custom includ wide varieti retail mail-ord pharmaci hospit network outpati
facil also offer value-ad servic pharmaci manag consult inventori
manag softwar drug commerci servic manufactur group purchas servic
physician practic
also occupi strong posit specialti pharmaceut distribut typic inject infus
drug especi oncology-rel servic specialti busi histor achiev faster
organ growth higher margin convent drug distribut busi
continu case futur year expect sale growth complex biolog drug significantli
outpac convent drug
custom concentr import awar ten largest account total
revenu fy sale two largest custom
script esrx account revenu respect
market profil return wareh logist inventori data servic drug distribut
contract typic pay distributor negoti percentag purchas order amount
multi-year period actual drug price usual negoti manufactur pharmaci
benefit manag arrang leav distributor price negoti elimin
price power view rise drug price typic lead larger whole dollar servic fee
distributor revers true drug price declin drug inflat also help distributor
tradit resal arrang purchas bulk inventori manufactur resel
downstream custom gain spread increas lower-cost exist inventori sold new
increas access health insur especi global middl class expand age develop
market popul posit long-term driver pharmaceut volum view drug
price critic factor profit recent year low price inflat brand drug
gener deflat result lower distribut fee negat postiv impact higher volum
distributor see shrink profit margin drug inflat keep pace rise
big pharmaceut distributor
form gener drug sourc joint ventur jv larg retail pharmaci began
collabor jv improv bargain power gener manufactur
similar jv walgreen respect three jv repres
three largest pharmaceut distributor retail pharmaci chain
increas bargain power jv manufactur like factor gener price
deflat trend last sever year contribut slower sale growth convent
pharmaceut turn led distributor seek higher growth margin non-tradit
drug busi specialti pharmaceut medic suppli
corpor strategi focus expand convent specialti pharmaceut
distribut busi recent expans busi includ pharmedium
lead provid specialti product acut care hospit acquir novemb
januari acquisit smith formerli largest privat held drug
distributor
also enter strateg relationship wherebi
becam primari distribut resourc intern pharmaci compani return
grant warrant purchas stake gradual increas ownership roughli
novemb sinc launch relationship fy revenu growth materi exceed
competitor fy particularli activ driven addit
distribut busi see potenti risk move forward howev independ pharmaci
may ultim steer busi away avoid send profit larg competitor
competit landscap price breadth product offer value-ad servic program
primari competit factor drug distribut industri big domin larg
multi-year contract consolid amongst downstream custom major impact
distributor earn case gain busi
pharmaci chain sold store prior transact rival provid
distribut servic store
financi trend fy achiev three-year compound annual growth rate
revenu adjust pre-tax incom per share adjust pre-tax incom margin around
fy fy per share earn growth aid roughli million net
share buyback fy view balanc sheet strong cash billion
decemb ebita-to-interest coverag
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
under-valued usd
neutral sinc march technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
distributor sub-industri next
month neutral base mainli
expect tepid growth prescript
drug volum continu
balanc solid growth fda novel drug
approv focu mainli drug
distribut busi compris
sale health care distribut
prescript drug volum seen meager
growth late expect even slower growth
come year estim
year-over-year growth total
toward end think
partli due slow growth
health-insur popul individu
health insur tend fill
prescript without due
lower out-of-pocket drug cost
view expect growth total enrolle
major health insur roughli
flat membership growth often aid
employ ad new hire
company-sponsor health plan robust
job gain may harder come
 economi near full employ
repeal individu mandat
may also begin contribut slower
beyond weak growth prescript volum
deflat gener drug price also
gener headwind distributor earn
case late monthli
year-over-year declin gener drug price
rang
continu sever deflationari trend
expect moder
gener drug deflat next year
howev pace gener approv
slow
histor lower gener approv activ
tend lessen competit gener drug
maker lead price power
expect deflat continu howev
less sever rate due signific price
power garner joint ventur
three major drug distributor three
walgreen
although may
seem counterintuit think power
jv exact price concess
gener maker hurt even drug
distributor apart jv
distributor fee often percentag
sale price trend view
distributor make volum
lost price enter jv
balanc neg see
sub-industri strong fda approv activ
novel drug fda approv new
drug increas
significantli
approv increasd demand driven
new drug potenti signific
tailwind drug distributor come
distributor fell vs rise
fell vs declin
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
et cfra keep hold recommend share
amerisourcebergen corpor lift target
ev/ebitda near high end rang
see valuat support made
take-over approach accord wall street journal
surpris decis seek acquir remain
alreadi although talk reportedli earli stage combin make
strateg sens us greater scale would help off-set drug reimburs
pressur perman secur relationship key drug
corpor rais target price-to-earnings
near low end abc five-year rang fy sep ep
estim see valuat hurt intens price
competit slow drug price inflat despit benefit
acquisit strength specialti drug see fy ep growth
support tax reform benefit partial off-set
suspens activ outsourc facil lift fy ep
dec-q ep vs estim
tax benefit /joseph agnes
et cfra keep hold opinion share
lower target price-to-earnings near
low end abc rang fy sep ep estim
see valuat hurt intens price competit
slow drug price inflat despit benefit acquisit strength
specialti drug set fy ep sep-q ep vs
estim revenu rose less expect
strength specialti drug non-drug distribut busi partial
off-set lower drug inflat increas gener convers /joseph
et cfra keep hold recommend share
corpor rais target
fy sept ep forecast -- histor forward price-to-earnings averag due
margin pressur expect lower fy ep estim
dec-q ep vs met
estim report solid revenu growth yoy dec-q although
estim organ growth roughli half exclud major
acquisit despit strong sale growth quarter
full year howev adjust pre-tax incom continu declin
drop yoy dec-q main culprit shrink margin
adjust gross margin cy cy think
stabil earn move past regulatori closur
pharmedium plant see limit growth ahead
consolid amongst upstream drugmak downstream payer like
continu pressur margin side /colin scarola
amerisourcebergen corpor lower
target fy sept ep forecast discount
histor averag due growth challeng expect lower
fy ep estim start sept-q ep
 miss consensu sale yoy sept-q
aid purchas largest independ drug distributor
retail pharmaci locat acquir largest
retail pharmaci custom earlier year despit strong revenu growth
howev estim yoy reduct adj pre-tax incom
pre-tax margin fell quarter margin continu
pressur gener drug price deflat greater well
oper challeng pharmedium plant think
difficulti gener earn growth revenu growth impact
 wear think gener deflat continu /colin
amerisourcebergen corpor cut target
price-to-earnings multipl ntm ep forecast lower
fy sep ep estim fy jun-q
ep beat estim howev view result
favor appli substanti discount forward price-to-earnings multipl
sever reason first view yoy revenu growth
quarter sustain due debt-fund acquisit
largest custom major factor second top-lin growth translat
oper earn growth margin pressur gener drug price
deflat doesnt look like let anytim soon third think
interest debt use fund acquisit employe sever
restructur cost includ oper earn better
assess growth factor account oper incom quarter
fell yoy rather remain flat report /colin scarola
et cfra keep hold opinion share
lower target price assum
forward ev/ebitda near high end trade rang
believ justifi potenti industri consolid despit
earn growth pressur see intens price competit slow
brand gener drug price inflat mar-q adjust ep vs
estim revenu grew estim
benefit recent acquisit growth largest custom
initi benefit complet
on-board retail pharmaci follow acquisit rite aid
store walgreen march margin narrow less expect benefit
recent acquisit stabil gener drug inflat rate
despit pressur suspens oper pharmedium
memphi distribut center expect becom fulli oper
fy sep /joseph agnes
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
